U.S. Patent Disclosures
Monday, April 16, 2012
Seaside Therapeutics Inc., of Cambridge, Mass., was granted U.S. Patent No. 8,143,311, titled "Methods of Treating Fragile X Syndrome and Autism." It covers the use of lead product GABA-B receptor agonist STX209 for the improvement of social and communication functions in autism.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.